Overview
Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3-FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.
Current Appointments & Affiliations
Associate Professor of Pediatrics
·
2012 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Associate Professor of Pharmacology and Cancer Biology
·
2012 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Associate Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
1999 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Roadmap for the next generation of Children's Oncology Group rhabdomyosarcoma trials.
Journal Article Cancer · November 15, 2024 Clinical trials conducted by the Intergroup Rhabdomyosarcoma (RMS) Study Group and the Children's Oncology Group have been pivotal to establishing current standards for diagnosis and therapy for RMS. Recent advancements in understanding the biology and cli ... Full text Link to item CitePreclinical development of a chimeric antigen receptor TÂ cell therapy targeting FGFR4 in rhabdomyosarcoma.
Journal Article Cell Rep Med · May 21, 2024 Full text Link to item CiteSpontaneous expression of the CIC::DUX4 fusion oncoprotein from a conditional allele potently drives sarcoma formation in genetically engineered mice.
Journal Article Oncogene · April 2024 CIC::DUX4 sarcoma (CDS) is a rare but highly aggressive undifferentiated small round cell sarcoma driven by a fusion between the tumor suppressor Capicua (CIC) and DUX4. Currently, there are no effective treatments and efforts to identify and translate bet ... Full text Link to item CiteRecent Grants
Validation of UM1 candidate targets in fusion-positive rhabdomyosarcoma preclinical models
ResearchPrincipal Investigator · Awarded by Massachusetts Institute of Technology · 2024 - 2029The Duke Preparing Research scholars In bioMEdical sciences (PRIME): Cancer Research Program
ResearchPreceptor · Awarded by National Cancer Institute · 2023 - 2028ASPET SURF Institutional Award
Inst. Training Prgm or CMEParticipating Faculty Member · Awarded by American Society for Pharmacology and Experimental Therapeutics · 2018 - 2028View All Grants
Education, Training & Certifications
Duke University ·
1995
M.D.
Duke University ·
1993
Ph.D.